AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

May 01, 2013

AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis

NORTH CHICAGO, Ill., May 1, 2013 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year.  

Apr 26, 2013

AbbVie Reports First-Quarter 2013 Financial Results

NORTH CHICAGO, Ill., April 26, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the first quarter ended March 31, 2013.

Apr 23, 2013

New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1

AMSTERDAM, April 23, 2013 /PRNewswire/ -- (NYSE: ABBV)  – Results from "Aviator,"  AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). In addition, similar high SVR rates observed after 12 and 24 weeks of treatment in the Phase IIb trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination.  The triple-DAA combination is currently being studied in Phase III clinical trials. Results will be featured in the official press conference at the 2013 International Liver Congress® (ILC) in Amsterdam on Wednesday, April 24 at 11:00 CEST and presented on Thursday, April 25.

Apr 17, 2013

Sofia Vergara Encourages Individuals with Hypothyroidism to "Follow the Script"

NORTH CHICAGO, Ill., April 17, 2013 /PRNewswire/ -- (NYSE: ABBV) - Emmy-nominated actress Sofia Vergara is helping to raise awareness about the importance of diagnosing and treating hypothyroidism, a thyroid condition that affects millions of Americans, through a new campaign called "Follow the Script." The campaign, made possible by AbbVie, aims to educate individuals with hypothyroidism about the importance of being consistent with the treatment their doctor prescribes, and provides a "script" to ensure they consistently receive the medication prescribed by their doctor when they visit the pharmacy.

Feb 20, 2013

UPDATE - Mar 5: Due to weather conditions, AbbVie will not be in attendance at Cowen Health Care Conference - AbbVie to Present at Cowen and Company 33rd Annual Health Care Conference

Feb 15, 2013

AbbVie Declares Dividend and Announces Share Repurchase Program

NORTH CHICAGO, Ill., Feb. 15, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend and also authorized a share repurchase program of up to $1.5 billion of the Company's outstanding common stock.

Jan 30, 2013

AbbVie Issues Inaugural Full-Year Outlook for 2013

NORTH CHICAGO, Ill., Jan. 30, 2013 /PRNewswire/ -- AbbVie today confirmed it delivered strong sales growth with its marketed pharmaceutical products in 2012.  The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent globally on an operational basis, excluding a nearly 3 percent negative impact from foreign exchange.   

Jan 21, 2013

AbbVie Named to S&P 500 Dividend Aristocrat Index

NORTH CHICAGO, Ill., Jan. 21, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, has been named to the S&P 500 Dividend Aristocrat Index for 2013.